Intercure annual stock-based compensation
2019
2020
2021
2022
2023
2024
2025
Intercure Stock-Based Compensation Growth & History (INCR)
Intercure's stock-based compensation was ₪2.4M for fiscal 2025.
View full Intercure company overviewIntercure annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | ₪2.4M | ₪148,000 | +6.49% |
| 2024 | 2024-12-31 | ₪2.3M | −₪311,000 | −12.00% |
| 2023 | 2023-12-31 | ₪2.6M | −₪6.3M | −70.90% |
| 2022 | 2022-12-31 | ₪8.9M | ₪2.5M | +38.05% |
| 2021 | 2021-12-31 | ₪6.5M | −₪3.6M | −35.53% |
| 2020 | 2020-12-31 | ₪10.0M | −₪58.0M | −85.29% |
| 2019 | 2019-12-31 | ₪68.0M | — | — |
Intercure stock-based compensation trends
Over the last five fiscal years, Intercure's stock-based compensation decreased from ₪10.0M to ₪2.4M, a change of −₪7.6M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Intercure source filings ↗Community posts
InterCure resolves Nasdaq minimum-bid-price deficiency
InterCure ($INCR) received written confirmation that it has regained compliance with Nasdaq’s minimum-bid-price requirement. Its shares had closed at or above $1 for ten consecutive business days, allowing Nasdaq to close the specific defic ...